Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 3/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28267871 | 0.86 | RIPK1 (0.41) | MAPTDPP4RIPK1 | |
| SCHEMBL2022033 | 0.83 | PKM (0.36) | MAPTEGFRERBB2PKMSLC6A2 | |
| SCHEMBL28269556 | 0.83 | ALOX15 (0.32) | SLC6A2SLC6A4KMT2ASLC6A3 | |
| SCHEMBL28267909 | 0.81 | IDO1 (0.44) | MAPTSLC6A2SLC6A4RIPK1SLC6A3 | |
| SCHEMBL28471761 | 0.80 | EGFR (0.34) | MAPTDPP4EGFRERBB2MEN1 | |
| SCHEMBL28269469 | 0.77 | TSHR (0.43) | EGFRERBB2PKMKMT2A | |
| SCHEMBL28269549 | 0.75 | PYCR1 (0.44) | — | |
| SCHEMBL28267850 | 0.73 | ALDH1A1 (0.46) | MAPTRIPK1MEN1KMT2A | |
| SCHEMBL28269455 | 0.72 | PTPRC (0.36) | MAPTPKMMEN1KMT2AGAA | |
| SCHEMBL25413733 | 0.72 | DPP4 (0.35) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340523-B2 | Certain dipeptidyl peptidase inhibitors | FOCHON PHARMA, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| EP-2521721-B1 | 3-(3-AMINOPIPERIDIN-1-YL)-5-OXO-1,2,4-TRIAZINE DERIVATES AS DIPEPTIDYL PEPTIDASE IV(DPP-IV) INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2014-10-01 | — | — | EP | disclosed |
| US-20140213590-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | FOCHON PHARMA, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8648073-B2 | Certain dipeptidyl peptidase inhibitors | FOCHON PHARMA, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2521721-A1 | 3-(3-AMINOPIPERIDIN-1-YL)-5-OXO-1,2,4-TRIAZINE DERIVATES AS DIPEPTIDYL PEPTIDASE IV(DPP-IV) INHIBITORS | Shanghai Fochon Pharmaceutical Co. Ltd (CN) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011079778-A1 | 3-(3-AMINOPIPERIDIN-1-YL)-5-OXO-1,2,4-TRIAZINE DERIVATES AS DIPEPTIDYL PEPTIDASE IV(DPP-IV) INHIBITORS | CHINA SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160212-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | FOCHON PHARMA, INC. | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160212-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP3, DPP8 | MAPT 3565/4885DPP4 1/4885EGFR 2867/4885 |
| US-20140213590-A1 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP3, DPP8 | MAPT 3565/4885DPP4 1/4885EGFR 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.